OncoMatch/Clinical Trials/NCT04646564
Radiotherapy for Extracranial Oligometastatic Breast Cancer
Is NCT04646564 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies standard of care for breast cancer metastatic.
Treatment: standard of care — More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic therapy alone, on survival, local control and toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. \>2), hormone receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Have received or plan to receive systemic therapy
Cannot have received: radiation therapy
Exception: for target area
Have received prior radiotherapy for target area
Lab requirements
Liver function
moderate/severe liver dysfunction (Child Pugh B or C) from liver metastases [excluded]
Have adequate organ function; Have moderate/severe liver dysfunction (Child Pugh B or C) from liver metastases [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify